- Home
- MCRB vs MCN Comparison
MCRB vs MCN Comparison
Compare MCRB & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- MCN
- Stock Information
- Founded
- MCRB 2010
- MCN 2004
- Country
- MCRB United States
- MCN Canada
- Employees
- MCRB N/A
- MCN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- MCN
- Sector
- MCRB Health Care
- MCN
- Exchange
- MCRB Nasdaq
- MCN Nasdaq
- Market Cap
- MCRB 141.9M
- MCN 135.8M
- IPO Year
- MCRB 2015
- MCN N/A
- Fundamental
- Price
- MCRB $0.80
- MCN $6.45
- Analyst Decision
- MCRB Buy
- MCN
- Analyst Count
- MCRB 4
- MCN 0
- Target Price
- MCRB $5.63
- MCN N/A
- AVG Volume (30 Days)
- MCRB 844.5K
- MCN 52.9K
- Earning Date
- MCRB 03-04-2025
- MCN 01-01-0001
- Dividend Yield
- MCRB N/A
- MCN 9.96%
- EPS Growth
- MCRB N/A
- MCN N/A
- EPS
- MCRB N/A
- MCN N/A
- Revenue
- MCRB $126,325,000.00
- MCN N/A
- Revenue This Year
- MCRB N/A
- MCN N/A
- Revenue Next Year
- MCRB N/A
- MCN N/A
- P/E Ratio
- MCRB N/A
- MCN N/A
- Revenue Growth
- MCRB 12856.41
- MCN N/A
- 52 Week Low
- MCRB $0.54
- MCN $6.69
- 52 Week High
- MCRB $1.53
- MCN $8.60
- Technical
- Relative Strength Index (RSI)
- MCRB 46.38
- MCN 34.87
- Support Level
- MCRB $0.81
- MCN $6.42
- Resistance Level
- MCRB $0.84
- MCN $6.49
- Average True Range (ATR)
- MCRB 0.04
- MCN 0.05
- MACD
- MCRB 0.00
- MCN 0.01
- Stochastic Oscillator
- MCRB 45.58
- MCN 24.92
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide a high level of current income and gains, with a secondary objective of capital appreciation.